Alan B. Colowick, MPH, MD
Director, Dimension Therapeutics
President for Europe, Mid-East, and Africa, Celgene
Alan B. Colowick, M.P.H., M.D., has served as a member of our board of directors since August 2015. Since 2010, Dr. Colowick has served in leadership roles at Celgene Corporation, a biotechnology company, where he most recently was president for the Europe, Mid-East, and Africa region from 2012 to 2014 and served as senior vice president Global Medical Affairs from 2010 to 2012. Previously, Dr. Colowick was chief executive officer of Gloucester Pharmaceuticals, LLC, a biotechnology company sold to Celgene in 2010, and president, oncology, for Geron Corporation, a biotechnology company, from 2006 to 2008 where he was responsible for the strategic and operational activities of the company’s oncology programs. Earlier in his career, Dr. Colowick held various management positions with Amgen Inc., a biopharmaceutical company, including vice president of European medical affairs. Dr. Colowick holds a B.S. degree in Molecular Biology from the University of Colorado, an M.D. from Stanford University and an M.P.H. from Harvard University. Dr. Colowick currently serves on the board of directors of Achaogen, Inc.
Mike Dybbs, PhD
Founding Partner, Samsara BioCapital
Mike Dybbs is a Founding Partner at Samsara BioCapital, a biotech investment firm launched in 2017. Prior to Samsara, Mike was a Partner at New Leaf Venture Partners (NLV) which he joined in 2009. In addition to Dimension, Mike has served on the boards of Versartis (VSAR), Advanced Cell Diagnostics and Principia. He has also been actively involved with NLV’s investments in: Synageva (GEVA), Karyopharm (KPTI), MEI Pharma (MEIP), Calithera (CALA), and Karus Therapeutics. Prior to joining NLV, Mike was a Principal at the Boston Consulting Group, where he was a core member of their Health Care practice and led projects in the biopharmaceutical industry across a range of functions and therapeutic areas. Mike received an A.B. in biochemical sciences from Harvard and a PhD in molecular biology from UC Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. His research was published in peer-reviewed journals, including Nature, Science, and Neuron.
Georges Gemayel, PhD
Director, Dimension Therapeutics
Georges Gemayel, Ph.D., has served as a member of our board of directors since August 2015. From February 2011 to December 2012, Dr. Gemayel served as executive chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. Prior to that, in 2010 Dr. Gemayel served as executive chairman of FoldRx Pharmaceuticals, Inc. until its acquisition by Pfizer Inc. From June 2008 until November 2009, Dr. Gemayel served as president and chief executive officer of Altus Pharmaceuticals Inc., a publicly traded pharmaceutical company. From 2003 to 2008, he was executive vice president at Genzyme Corporation where he was responsible for Genzyme Corporation’s global therapeutics, transplant, renal and biosurgery businesses. From 2000 to 2003, Dr. Gemayel was employed as vice president, national specialty care, for Hoffmann La-Roche Inc., responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis and HIV. Dr. Gemayel joined Hoffmann-La Roche Inc. in 1988 and served in various positions of increasing responsibility over his tenure there. Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon and his Ph.D. in pharmacology from Paris-Sud University in Paris, France. Dr. Gemayel currently serves as chairman of the boards of directors of OxThera AB, Enterome Bioscience SA and Orphazyme ApS, all privately held companies, and on the boards of directors of Raptor Pharmaceuticals Corp. and Supernus Pharmaceuticals, Inc. He was previously a director of Adolor Corporation, a publicly traded clinical development company acquired by Cubist Pharmaceuticals, Inc., a director at Prosensa Holding N.V., which was acquired by BioMarin Pharmaceutical Inc., a director at NPS Pharmaceuticals, Inc., which was acquired by Shire plc., the chairman of EpiTherapeutics ApS, which was acquired by Gilead Sciences, Inc., and the chairman of Vascular Magnetics, Inc. a privately owned company.
Rishi Gupta, JD
Private Equity Partner, OrbiMed
Rishi Gupta is a private equity partner at OrbiMed and has been with the firm since 2003. Prior to OrbiMed, he was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine and was a summer associate at Wachtell, Lipton, Rosen & Katz. Mr. Gupta has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world.
In addition to Dimension, Mr. Gupta serves or has served on the boards of Sientra, Symbiomix Therapeutics, Avitide, and ChemoCentryx. He has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, and Invitae.
Mr. Gupta received his A.B. degree magna cum laude in biochemical sciences from Harvard College and holds a J.D. from the Yale Law School.
John Hohneker, MD
President, Head of Research and Development,
FORMA Therapeutics Inc.
John Hohneker, M.D., has served as a member of our board of directors since January 2017. Dr. Hohneker joined FORMA Therapeutics Inc. in 2015 with over 25 years of drug development experience in the pharmaceutical industry across a broad range of therapeutic areas, including oncology, immunology, dermatology, rheumatology, and organ transplantation. He has played a critical role in advancing therapeutics from preclinical through health authority approval, including 17 drug launches. Dr. Hohneker held various leadership positions at Novartis from 2001 to 2015. Most recently, as Senior Vice President and Global Head of Development, Immunology and Dermatology, where he was responsible for the global development of the immunology, rheumatology, and dermatology product pipelines including the recent approvals and launches of Cosentyx®, Xolair® and Ilaris®. Previously he also served as Senior Vice President of U.S. Oncology Clinical Development and Medical Affairs where he played a key role in the development, approval, and/or commercialization of several important oncology products such as Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®. Prior to joining Novartis, Dr. Hohneker spent approximately 11 years at Glaxo Wellcome and its legacy company Burroughs Wellcome in various roles of increasing responsibility, including Worldwide Therapeutic Head, Director, Oncology Clinical Development and led the approval of Navelbine®. He has also served on the research committee of the American Society of Clinical Oncology and the Institute of Medicine’s Cancer Policy Forum. He also held a faculty position at the University of North Carolina School of Medicine at Chapel Hill, N.C.
Dr. Hohneker received a bachelor’s degree in chemistry from Gettysburg College, Gettysburg, PA., and M.D. from the University of Medicine and Dentistry of New Jersey, Rutgers Medical School (Robert Wood Johnson Medical School), Piscataway, N.J. He completed his internship and residency in internal medicine and his fellowship in medical oncology all at the University of North Carolina Hospitals at Chapel Hill, N.C.
Annalisa Jenkins, MBBS, FRCP
Chief Executive Officer, Dimension
Dr. Annalisa Jenkins, MBBS, FRCP is the chief executive officer of Dimension. A biopharma thought leader with nearly 20 years of industry experience, Dr. Jenkins has built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Prior to joining Dimension, Dr. Jenkins served as executive vice president, head of Global Research and Development for Merck Serono. She also led Global Medical Affairs and Quality and was a member of Merck Serono’s Pharmaceutical Executive Committee. Previously, Dr. Jenkins pursued a nearly 15-year career at Bristol-Myers Squibb (BMS), attaining the role of senior vice president and head of Global Medical Affairs. She began her career as a medical officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. Dr. Jenkins graduated in medicine from St. Bartholomew’s Hospital London and trained in cardiovascular medicine in the UK National Health Service.
Dr. Jenkins is a member of the Board of Directors of Ardelyx, Biothera, MedCity, and Viventia Bio, Inc. She also is a member of the European Commission’s Scientific Panel for Health, a science-led expert group tasked with helping to achieve better health and wellbeing for all. In addition, Dr. Jenkins is a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues.
Executive Vice President and Chief Financial Officer, Dyax Corp.
George Migausky has served as Executive Vice President and Chief Financial Officer (CFO) since joining Dyax in August 2008. Prior to joining Dyax, Mr. Migausky served as CFO of Wellstat Management Company, a privately-held company responsible for the strategy, business development and operations of an affiliated group of five life science companies.
From 1990 to 2004, he served as CFO at IGEN International where he was instrumental in preparing the Company for its initial public offering in 1994, its merger with F. Hoffman La Roche in 2004 and the simultaneous spinoff of BioVeris Corporation as an independent public company. He served as CFO of BioVeris through to 2008. Mr. Migausky received an MBA from Babson College and a BS from Boston College.
Arlene M. Morris
Director, Dimension Therapeutics
Arlene M. Morris has served as a member of our board of directors since August 2015. Ms. Morris was previously the chief executive officer of Syndax Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, president from September 2013 to June 2015 and a member of the board of directors from May 2011 to June 2015. From 2003 to January 2011, Ms. Morris served as the president, chief executive officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Neovacs, SA, a French publicly traded biotechnology company, Biodel, Inc. and Palatin Technologies, Inc., both U.S. biopharmaceutical companies. She is also on the board of the Foundation for Research Development of the Medical University of South Carolina. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.